🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› México
Clinical trial register · Mexico

Clinical Trials in México, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Mexico and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1579 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:45 UTC
1579
Studies in scope
all four open statuses
711
Recruiting now
open to new participants
247
Lead sponsors
across recruiting studies
Top sites
Mexico City 586 Monterrey 370 Guadalajara 342 Chihuahua City 175 Mérida 135
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca26 Boehringer Ingelheim9 Hoffmann-La Roche8 Janssen Research & Development, LLC5 Gilead Sciences5
Site location
Mexico City586 Monterrey370 Guadalajara342 Chihuahua City175 Mérida135
All 197 locations
Target enrolment
to

Trials with a site in México

99 of 1579 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Mexico
Start
Not yet open
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
2,380
Aguascalientes, Chihuahua City, México, Metepec, Guadalajara, Morelia, Monterrey, Oaxaca City
2026-12-16
Recruiting
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
NCT07412704Arthritis, Rheumatoid
Bristol-Myers Squibb
Phase 1/2
84
México
2026-09-15
Recruiting
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
NCT07624305Renal Insufficiency, Chronic
DrugsBalcinrenone/dapagliflozin·Dapagliflozin
AstraZeneca
Phase 3
2,800
Benito Juárez, Culiacán, Durango, Ecatepec de Morelos, Estado de México, Mexico City, México, Tuxpan
2026-09-01
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Guadalajara, México, Monterrey, Querétaro, San Luis Potosí City, Tijuana, Xalapa, Zapopan
2026-08-24
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)
DrugsObrixtamig·Etoposide·Carboplatin
Boehringer Ingelheim
Phase 3
390
Guadalajara, Jalisco, Mexico City, México, Toluca, Zapopan
2026-07-10
Recruiting
A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
NCT07598396Lupus, Systemic Lupus Erythematosus, Lupus Nephritis
DrugMosunetuzumab
Hoffmann-La Roche
Phase 2
30
Torreón, Mexicali, Guadalajara, México, Culiacán
2026-05-25
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin
Boehringer Ingelheim
Phase 3
670
Guadalajara, Jalisco, Mexico City, México, Monterrey, Nuevo León, Toluca
2026-04-13
Recruiting
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
NCT07430306Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
245
Culiacán, Durango, Guadalajara, Mérida, México
2026-04-13
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058Obesity or Overweight, Type 2 Diabetes Mellitus
Hoffmann-La Roche
Phase 3
1,600
Col Saucito, Guadalajara, México, Delegacion Cuauhtemoc, Cuernavaca, San Pedro Garza García, Ciudad Madero
2026-03-23
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045Obesity or Overweight
Hoffmann-La Roche
Phase 3
2,000
Col Saucito, Guadalajara, Delegacion Cuauhtemoc, México, Cuernavaca, San Pedro Garza García, Ciudad Madero
2026-03-16
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695Non-small Cell Lung Cancer
DrugsZongertinib·Atezolizumab·Durvalumab·Nivolumab
Boehringer Ingelheim
Phase 3
400
Jalisco, Mexico City, México, Monterrey
2026-01-16
Recruiting
Telerehabilitation Program to Improve Function in People With Chronic Low Back Pain Compared With Conventional Care
NCT07248813Chronic Low Back Pain (Non-specific, Uncomplicated)
Coordinación de Investigación en Salud, Mexico
Not applicable
200
México
2025-10-03
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884Urinary Incontinence,Stress
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,000
Chihuahua City, Ciudad Madero, Juriquilla, Mexico City, Mérida, México, Monterrey, Morelia
2025-09-30
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsTacabrutideg·Pirtobrutinib
BeOne Medicines
Phase 3
500
México, Monterrey, Oaxaca City, Toluca
2025-09-04
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
11,800
Chihuahua City, Cuernavaca, Culiacán, Guadalajara, Mexico City, Mérida, México, Monterrey
2025-07-22
Recruiting
Family-Based Nutrition Intervention to Prevent Overweight and Obesity in School-Age Children.
NCT07159971Overweight and/or Obesity, Children - Malnutrition, Preventing Malnutrition
Claudia Teresa Tovar Palacio
Not applicable
40
México
2025-06-30
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370Heart Failure
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
4,200
Aguascalientes, Culiacán, Guadalajara, Irapuato, México, Monterrey, Querétaro, Tijuana
2025-05-20
Active, closed
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
NCT06806852Head and Neck Squamous Cell Carcinoma
DrugsBI 770371·Cetuximab·Pembrolizumab
Boehringer Ingelheim
Phase 1
91
Mexico City, México, Tlajomulco de Zuñiga
2025-05-14
Recruiting
Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity
NCT07018622Solid Tumors, Cisplatin Nephrotoxicity
DrugsOlaparib·Dapagliflozin
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phase 2
46
México
2025-05-07
Recruiting
Metabolic Effect of Exercise and Diet in Endometrial Cancer Patients Eligible for Staging Surgery.
NCT07025213Endometrial Cancer
National Institute of Cancerología
Not applicable
80
México
2025-04-02
Recruiting
Efficacy and Safety of Vitamin D Supplementation in Pediatric Patients with Obesity
NCT06847373Vitamin D, Insulin Resistance, Obesity, Childhood
Coordinación de Investigación en Salud, Mexico
Not applicable
40
México
2025-03-01
Recruiting
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
NCT06747949Sjögren's Syndrome
DrugDazodalibep
Amgen
Phase 3
844
Parques de San Felipe, Mexicali, Guadalajara, Mexico City, Mérida, México
2025-02-25
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
655
Culiacán, Guadalajara, Mexico City, Mexico D F, Mérida, México, Querétaro, San Luis Potosí City
2024-12-04
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386Non-small Cell Lung Cancer
DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin
Bristol-Myers Squibb
Phase 3
1,000
Guadalajara, México, Querétaro, San Luis Potosí City
2024-10-07
Active, closed
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)
DrugZiltivekimab
Novo Nordisk A/S
Phase 3
10,000
Aguascalientes, Torreón, Guadalajara, México, Tlalpan, Cuauhtémoc, Monterrey, Culiacán
2024-06-25
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449Polymyositis, Dermatomyositis
AstraZeneca
Phase 3
240
Culiacán, D.F, Guadalajara, Mexico City, México
2024-06-20
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288Heart Failure
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
6,712
Aguascalientes, Culiacán, Distrito Federal, Guadalajara, Irapuato, México, Monterrey, Tlalnepantla
2024-06-17
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972Systemic Lupus Erythematosus
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
550
León, Guadalajara, Mexico City, Morelia, Mérida, México
2024-05-21
Recruiting
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
NCT06361537Acute Hereditary Angio Edema
Octapharma
Phase 3
124
Mexico City, México
2024-04-30
Recruiting
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064Recurrent or Metastatic Solid Tumors
DrugIfinatamab Deruxtecan
Daiichi Sankyo
Phase 1/2
680
Mérida, México
2024-04-10
Active, closed
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
NCT06245408Sjögren's Syndrome (SS)
DrugDazodalibep
Amgen
Phase 3
434
Parques de San Felipe, Torreón Centro, Mexicali, Americana, Mexico City, San Miguel Chapultepec, Centro, México
2024-04-08
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
100
Atizapán de Zaragoza, Guadalajara, Mérida, México, Monterrey
2024-03-14
Active, closed
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574Lung Cancer, Non-squamous, Non-small Cell
DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin
Boehringer Ingelheim
Phase 3
428
Mexico City, México, Veracruz
2024-02-09
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
DrugsDatopotamab Deruxtecan·Durvalumab·Nab-paclitaxel·Gemcitabine
AstraZeneca
Phase 3
625
CD Mexico, Guadalajara, Mexico City, México, Tuxtla Gutiérrez
2023-11-23
Active, closed
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915Sjogrens Syndrome
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
612
Guadalajara, Mexico City, Culiacán, Mérida, México
2023-10-27
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578Progressive Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,057
Aguascalientes, México, Guadalajara, Morelia, Oaxaca City, Córdoba, Mérida, Chihuahua City
2023-10-25
Recruiting
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
NCT06079671Locally Advanced Cervical Cancer
DrugVolrustomig
AstraZeneca
Phase 3
800
Coyoacán, Culiacán, Guadalajara, Guadalajra, Mexico City, México, Monterrey
2023-09-22
Recruiting
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617Primary Biliary Cholangitis
DrugSeladelpar
Gilead Sciences
Phase 3
402
Cuernavaca, Irapuato, Mexico City, México, Oaxaca City, Veracruz
2023-09-07
Recruiting
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
NCT06126224Psychosis Associated With Alzheimer's Disease
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
500
Saltillo Centro, Zona Urbana Río Tijuana, Zapopan, Monterrey, Culiacán, México
2023-08-28
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949Psychosis Associated With Alzheimer's Disease
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Saltillo Centro, Zona Urbana Río Tijuana, Zapopan, Monterrey, Culiacán, México
2023-07-11
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
DrugsSacituzumab Govitecan·Nab-paclitaxel·Capecitabine·Paclitaxel
Gilead Sciences
Phase 3
654
Cancún, Mexico City, México, Monterrey, Puebla City, San Pedro Garza García, Yucatán
2023-05-08
Active, closed
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
NCT05624749Systemic Lupus Erythematosus
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
288
León, Guadalajara, Mexico City, Morelia, Mérida, México
2023-04-21
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
4,300
Aguascalientes, Alc. Cuauhtémoc, Colonia Lindavista, Mexico City, Mérida, México, Monterrey, San Luis Potosí City
2023-03-31
Active, closed
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
NCT05612035Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Merck Sharp & Dohme LLC
Phase 2
129
Mexico City, Hacienda de Las Palmas, México
2023-03-16
Recruiting
Improving Lifestyle Behavior by "Joven, Fuerte y Saludable" Multidisciplinary Program.
NCT06090747Breast Neoplasm
Instituto Nacional de Cancerologia de Mexico
Not applicable
146
México
2023-03-09
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
DrugsDatopotamab Deruxtecan·Durvalumab·Pemetrexed·Paclitaxel
AstraZeneca
Phase 3
1,350
Del. Cuauhtemoc, Mexico City, México, San Luis Potosí City
2022-12-29
Active, closed
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237Non-small Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed
Gilead Sciences
Phase 3
1,021
México, Mitras Centro, Oaxaca City, Orizaba Centro, Puebla City, Veracruz
2022-10-12
Active, closed
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
NCT05540327Systemic Lupus Erythematosus
DrugEnpatoran
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2
379
Cuernavaca, Guadalajara, Mexicali, Mexico City, Mérida, México, Monterrey, Torreón
2022-09-16
Active, closed
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
NCT05349214Sjogren Syndrome
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
506
Culiacán, Mérida, México
2022-08-04
Active, closed
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286Triple Negative Breast Cancer, PD-L1 Positive
DrugsAbraxane·Taxol·Sacituzumab Govitecan·Nab-paclitaxel
Gilead Sciences
Phase 3
443
Chihuahua City, Culiacán, Guadalajara, Mexico City, Mérida, México, Monterrey, San Luis Potosí City
2022-07-25
Active, closed
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299Triple Negative Breast Cancer, PD-L1 Negative
DrugsAbraxane·Sacituzumab Govitecan·Nab-paclitaxel·Gemcitabine
Gilead Sciences
Phase 3
623
Chihuahua City, Culiacán, Guadalajara, Mexico City, Mérida, México, Monterrey, San Luis Potosí City
2022-07-20
Active, closed
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
NCT05379634Myositis
DrugNipocalimab
Janssen Research & Development, LLC
Phase 2
36
Guadalajara, Mexico City, México
2022-07-05
Recruiting
Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer
NCT06883409Ovarian Neoplasms
Instituto Nacional de Cancerologia de Mexico
Not applicable
33
México
2022-05-19
Active, closed
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512Breast Cancer
DrugsEribulin·Datopotamab Deruxtecan·Nab-paclitaxel·Capecitabine
AstraZeneca
Phase 3
644
CD Mexico, Guadalajara, Guadalajara Jalisco, Mexico City, México
2022-05-16
Active, closed
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004Multiple Sclerosis
DrugOcrelizumab
Hoffmann-La Roche
Phase 3
1,300
Guadalajara, Mexico City, Tlalnepantla, Monterrey, Culiacán, Chihuahua City, México
2022-05-03
Active, closed
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
NCT05171647Non-Hodgkin Lymphoma
DrugsMosunetuzumab·Polatuzumab Vedotin·Tocilizumab·Rituximab
Hoffmann-La Roche
Phase 3
208
Mexico City, Monterrey, Distrito Federal, México
2022-04-25
Active, closed
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842Hepatocellular Carcinoma
DrugsTremelimumab·Lenvatinib·Durvalumab
AstraZeneca
Phase 3
760
Guadalajara, Jalisco, México, San Luis Potosí City, Tuxtla Gutiérrez
2022-03-28
Active, closed
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577Prostate Cancer
DrugsCapivasertib·Docetaxel
AstraZeneca
Phase 3
1,035
Aguascalientes, Culiacán, Guadalajara, Mexico City, México, Oaxaca City, Zapopan
2022-03-25
Active, closed
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133Lupus Nephritis
DrugAnifrolumab
AstraZeneca
Phase 3
363
Chihuahua City, Guadalajara, México, San Luis Potosí City
2022-02-15
Active, closed
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 3
776
Guadalajara, León, México, Naucalpan
2021-11-17
Active, closed
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
NCT04958239Neoplasms
DrugsEzabenlimab·Pembrolizumab
Boehringer Ingelheim
Phase 1
151
Mexico City, México, Monterrey
2021-10-18
Active, closed
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice
NCT05049798Arthritis, Psoriatic
DrugsIL-17i·Tremfya·Guselkumab
Janssen Pharmaceutica N.V., Belgium
Observational
1,314
Mérida, México, Zapopan
2021-08-25
Recruiting
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
NCT04965675Chronic Migraine in Children
DrugEptinezumab
H. Lundbeck A/S
Phase 3
285
Guadalajara, Zapopan, Morelia, Monterrey, Culiacán, México, Chihuahua City, Durango
2021-06-30
Active, closed
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
NCT04877691Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
367
Chihuahua City, Culiacán, Durango, Guadalajara, Mexicali, Mérida, México
2021-06-08
Active, closed
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT04822181Non-alcoholic Steatohepatitis
DrugSemaglutide
Novo Nordisk A/S
Phase 3
1,205
Acapulco de Juárez, Guadalajara, Mexico City, Monterrey, San Pedro Garza García, Culiacán, Mérida, México
2021-04-01
Active, closed
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
NCT04586023Relapsing Multiple Sclerosis
DrugsFenebrutinib·Teriflunomide
Hoffmann-La Roche
Phase 3
751
Mexico City, México, Chihuahua City
2021-03-24
Active, closed
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
NCT04548999Multiple Sclerosis
DrugsOcrelizumab·Methylprednisolone
Hoffmann-La Roche
Phase 3
769
Guadalajara, Mexico City, San Luis Potosí City, México
2020-12-03
Active, closed
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
NCT04544449Multiple Sclerosis, Primary Progressive
DrugsFenebrutinib·Ocrelizumab
Hoffmann-La Roche
Phase 3
985
Mexico City, México, Tialnepantla
2020-10-26
Active, closed
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04538664Carcinoma, Non-Small-Cell Lung
DrugsAmivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 3
308
Chihuahua City, Guadalajara, Mexico City, México, Monterrey, Naucalpan
2020-10-13
Active, closed
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Osimertinib
Janssen Research & Development, LLC
Phase 3
1,074
Guadalajara, León, Mexico City, México, Monterrey, Naucalpan
2020-09-30
Active, closed
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
NCT04494425Advanced or Metastatic Breast Cancer
DrugsTrastuzumab deruxtecan·Nab-paclitaxel·Capecitabine·Paclitaxel
AstraZeneca
Phase 3
866
Alc. Cuauhtémoc, Guadalajara Jalisco, Guadalajra, Mexico City, México, Monterrey, Nuevo León
2020-07-24
Active, closed
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
NCT04273945Pulmonary Arterial Hypertension
DrugMacitentan
Actelion
Phase 3
935
Guadalajara, Mexico City, México, Monterrey, Morelia
2020-06-30
Active, closed
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
NCT04269200Endometrial Neoplasms
DrugsOlaparib·Durvalumab·Paclitaxel·Carboplatin
AstraZeneca
Phase 3
805
Aguascalientes, México, Monterrey, Oaxaca City, Querétaro, San Luis Potosí City, Veracruz
2020-05-05
Active, closed
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
NCT03937154Chemotherapy-induced Thrombocytopenia
DrugsNplate·Romiplostim
Amgen
Phase 3
145
La Paz, San Luis Potosí City, Cuautitlán Izcalli, México, Oaxaca City, Toluca
2020-02-26
Active, closed
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT04088396Systemic Juvenile Idiopathic Arthritis
DrugsBaricitinib·Tocilizumab
Eli Lilly and Company
Phase 3
58
Chihuahua City, Durango, Guadalajara, México, Monterrey
2020-02-12
Active, closed
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
NCT04175600Hypertension, Pulmonary
DrugSelexipag
Actelion
Phase 3
138
Guadalajara, México, Monterrey
2020-01-16
Active, closed
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
NCT03687359Dermatitis Atopic
Sanofi
Observational
1,860
Cuernavaca, Monterrey, México, Puebla City, Tlalnepantla
2019-08-15
Active, closed
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
NCT03997123Triple Negative Breast Neoplasms
DrugsCapivasertib·Paclitaxel
AstraZeneca
Phase 3
923
Aguascalientes, Estado de México, Guadalajara, México, Monterrey, Tuxtla Gutiérrez
2019-06-25
Recruiting
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
NCT03773965Juvenile Idiopathic Arthritis
DrugBaricitinib
Eli Lilly and Company
Phase 3
190
Chihuahua City, Durango, Guadalajara, México, Monterrey
2019-04-05
Active, closed
Avelumab Program Rollover Study
NCT03815643Solid Tumors
DrugAvelumab
EMD Serono Research & Development Institute, Inc.
Phase 3
205
México
2019-03-22
By invitation
Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS
NCT03856229Pneumocystis, HIV/AIDS, Steroid
Centro de Investigación en. Enfermedades Infecciosas, Mexico
Not applicable
196
México
2019-03-04
Active, closed
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
NCT03742895Advanced Solid Neoplasms
DrugOlaparib
Merck Sharp & Dohme LLC
Phase 2
329
Guadalajara, Monterrey, Santiago de Quetaro, Madero, Chihuahua City, Mexico City, México, Oaxaca City
2018-12-12
Active, closed
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
NCT03800134Non-Small Cell Lung Cancer
DrugsDurvalumab·Pemetrexed·Gemcitabine·Paclitaxel
AstraZeneca
Phase 3
825
Aguascalientes, Chihuahua City, Guadalajara, México, Monterrey, Pachuca
2018-12-06
Active, closed
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
NCT03778957Hepatocellular Carcinoma
DrugsAvastin·Durvalumab·Bevacizumab
AstraZeneca
Phase 3
724
Alc. Cuauhtémoc, Culiacán, Guadalajara, Mérida, México, Monterrey, Tuxtla Gutiérrez
2018-11-30
Active, closed
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
NCT03706690Carcinoma, Non-Small-Cell Lung
DrugDurvalumab
AstraZeneca
Phase 3
407
Culiacán, Mexico City, México, Monterrey, San Luis Potosí City
2018-11-27
Recruiting
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases
NCT03549754Type 2 Diabetes, Hypertension, Chronic Kidney Disease, Heart Failure
AstraZeneca
Observational
35,000
León, Iztapalapa, Mexico City, México
2018-02-17
Active, closed
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
DrugsIvosidenib·Azacitidine
Institut de Recherches Internationales Servier
Phase 3
146
Culiacán, México
2017-06-26
Active, closed
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
NCT03164616Non Small Cell Lung Cancer NSCLC
DrugsAbraxane·Tremelimumab·Durvalumab·Pemetrexed
AstraZeneca
Phase 3
1,186
Aguascalientes, Cuautitlán Izcalli, Guadalajara, Mexico City, México, Monterrey, Tuxtla Gutiérrez
2017-06-01
Active, closed
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
NCT02972840Lymphoma, Mantle Cell
DrugsAcalabrutinib·Bendamustine·Rituximab
Acerta Pharma BV
Phase 3
635
Mexico City, México, Monterrey, Querétaro
2017-04-05
Active, closed
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
NCT02489318Prostate Cancer
DrugApalutamide
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Durango, Guadalajara, León, Mexico City, México, Morelia, Zapopan
2015-11-27
Active, closed
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
NCT02531516Prostatic Neoplasms
DrugsGnRH·Bicalutamide·Apalutamide
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Culiacán, Guadalajara, León, México, Morelia, Zapopan
2015-11-19
Active, closed
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
NCT02542293Non Small Cell Lung Carcinoma NSCLC
DrugsTremelimumab·Durvalumab·Pemetrexed·Gemcitabine
AstraZeneca
Phase 3
953
Acapulco, Aguascalientes, Mérida, México, Monterrey
2015-11-03
Active, closed
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
NCT02516241Urothelial Cancer
DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin
AstraZeneca
Phase 3
1,126
Guadalajara, León, Mexico City, México, Monterrey
2015-11-02
Active, closed
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
NCT02362503HIV Infections
ViiV Healthcare
Phase 3
371
Chihuahua City, Distrito Federal, Guadajalara, Mexico City, México
2015-02-23
Active, closed
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT02257736Prostatic Neoplasms
DrugsZytiga·Apalutamide·Abiraterone acetate·Prednisone
Aragon Pharmaceuticals, Inc.
Phase 3
982
Chihuahua City, Cuernavaca, Culiacán, México, Oaxaca City, Zapopan
2014-11-26
Active, closed
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
NCT02246621Breast Cancer
DrugsAnastrozole·Abemaciclib·Letrozole
Eli Lilly and Company
Phase 3
493
Torreón, México, León, Guadalajara, Mexico City, Cuernavaca, Juchitán de Zaragoza, Colinas Del Cimatario
2014-11-06
Active, closed
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
NCT01933932Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
DrugsPegfilgrastim·Selumetinib·Docetaxel
AstraZeneca
Phase 3
510
México, Monterrey
2013-09-25
Active, closed
Male Breast Cancer: Understanding the Biology for Improved Patient Care
NCT01101425Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Observational
200
México
2010-12
Active, closed
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
NCT00099437Breast Cancer
DrugFulvestrant
AstraZeneca
Phase 3
736
Mexico City, México
2005-02-13
Rows per page Showing 1–99 of 99
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Mexican investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-mexico/city/m-xico

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Mexico and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,579 studies in total at the last sync on 26 Sep 2026, 19:45 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 99 of those studies with a site in México.

How many clinical trials are recruiting in México?

38 of the 99 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:45 UTC sync. A further 1 have not yet opened recruitment, 59 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (México), 99 studies
PhaseStudiesRecruitingShare
Phase 3782778.8%
Not applicable767.1%
Phase 2626.1%
Observational414%
Phase 1202%
Phase 1/2222%

Most active sponsors

Lead sponsors with the most studies (México)
Lead sponsorStudiesRecruiting
AstraZeneca269
Boehringer Ingelheim96
Hoffmann-La Roche83
Gilead Sciences51
Janssen Research & Development, LLC50
Bristol-Myers Squibb42
Eli Lilly and Company42
Novartis Pharmaceuticals41
Amgen31
Aragon Pharmaceuticals, Inc.30
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.